The DOI matches its Crossref record; 61 of the 62 references it cites were found in a registry or an index; none of the 21 sources its claims cite is checked for support yet.
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Open accessAbstract
&NA; Anti‐PD‐1 immune checkpoint blockers can induce sustained clinical responses in cancer but how they function in vivo remains incompletely understood. Here, we combined intravital real‐time imaging with single‐cell RNA sequencing analysis and mouse models to uncover anti‐PD‐1 pharmacodynamics directly within tumors. We showed that effective antitumor responses required a subset of tumor‐infiltrating dendritic cells (DCs), which produced interleukin 12 (IL‐12). These DCs did not bind anti‐PD‐1 but produced IL‐12 upon sensing interferon &ggr; (IFN‐&ggr;) that was released from neighboring T cells. In turn, DC‐derived IL‐12 stimulated antitumor T cell immunity. These findings suggest that full‐fledged activation of antitumor T cells by anti‐PD‐1 is not direct, but rather involves T cell:DC crosstalk and is licensed by IFN‐&ggr; and IL‐12. Furthermore, we found that activating the non‐canonical NF‐&kgr;B transcription factor pathway amplified IL‐12‐producing DCs and sensitized tumors to anti‐PD‐1 treatment, suggesting a therapeutic strategy to improve responses to checkpoint blockade. Graphical Abstract Figure. No caption available. HighlightsEffective anti‐PD‐1 anti‐tumor responses require IL‐12‐producing dendritic cellsAnti‐PD‐1 indirectly activates IL‐12 through IFN‐&ggr; produced from CD8+ T cellsAgonizing the non‐canonical NF‐&kgr;B pathway enhances dendritic cell IL‐12 productionCombining aPD‐1 with non‐canonical NF‐&kgr;B agonism enhances checkpoint immunotherapy &NA; Anti‐PD‐1 mAbs can induce sustained clinical responses in cancer but how they function in vivo remains incompletely understood. Garris et al. show that effective anti‐PD‐1 immunotherapy requires intratumoral dendritic cells (DCs) producing IL‐12. Anti‐PD‐1 indirectly activates DCs through IFN‐&ggr; released from drug‐activated T cells. Furthermore, agonizing the non‐canonical NF‐&kgr;B pathway activates DCs and enhances aPD‐1 therapy in an IL‐12‐dependent manner.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 21 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Stimulated CD8+ T cells substantially increased IFN-γ production in the presence of IL-12 (Figure 4C)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we did not find evidence of IFN-γ or IL-12 induction by aPD-1 in the local draining lymph node (Figure S4A and B)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Flow cytometry analysis confirmed these cells to be MHC class II+ F4/80– (Figure S1D)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IL-12p40-eYFP+ cells displayed a branched morphology (mean circularity index: 0.54 ± 0.4), suggesting they were DCs.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Successful aPD-1 treatment triggers endogenous IFN-γ and IL-12 responses within tumors
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“parabiosis of tumor-bearing mice indicated that these cells could derive from a blood circulating precursor (Figure S1E).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that intratumoral IL-12 substantially expanded IFN-γ-eYFP+ cells (5.9 ± 0.7 fold increase by day four; Figure 4A).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“scRNAseq data indicated that aPD-1 treatment triggered the proliferation of tumor-infiltrating CD8+ T cells (Figure S4C).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and were unresponsive to aPD-1 treatment (Figure 3F)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IFN-γ sensing by DCs controls IL-12 production
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“blocking lymphocyte recirculation through treatment with the trafficking inhibitor FTY 720 did not affect the antitumor response to aPD-1 treatment (Figure S4D and E).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“we found that IL-12+ DCs expressed CD103 in lung tumor models (Figure S2D).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes
- It may state two separate claims as one. 32
- Probably not a substantial claim. 21
- The quote only partly states this claim. 1
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Intravital imaging of the tumor microenvironment revealed a 6.0 ± 1.1 (mean ± SEM) fold expansion of IFN-γ- eYFP+ cells one day after a single aPD-1 injection; this increase was sustained for up to 3 days post treatment (Figure 1B and S1A).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Successful aPD-1 treatment triggers endogenous IFN-γ and IL-12 responses within tumors
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The ability for IL-12+ cells to accumulate within tumors was supported by the real-time imaging observation that these cells were motile one day after aPD-1 treatment (motility coefficient: ~10 µm2/min; Figure 1G-H and Supplemental Video 1) and much less so on day five (<1 µm2/min; Figure 1G-H and Supplemental Video 2).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Successful aPD-1 treatment triggers endogenous IFN-γ and IL-12 responses within tumors
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Both DC subsets were largely negative for the macrophage colony-stimulating factor receptor Csf1r (Figure 2C), although some DC2s expressed this receptor (Figure S2A), similarly to a subset of intratumoral DCs previously reported (Broz et al., 2014).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
What the sources say
- Not checked yetcites Broz et al., 2014 source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Both DC1s and DC2s expressed the DC markers Batf3, Flt3, H2-Dmb2 and Zbtb46 (Meredith et al., 2012; Hildner et al., 2008;); DC1 expressed Fscn1 and Ly 75 (DEC-205) whereas DC2s expressed CD209a (DC- SIGN), Mgl2 (CD301b) and Cd24a (Figure 2B and Figure S2B).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
What the sources say
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and DC1s and DC2s expressed distinct chemokines and chemokine receptors (Figure 2E).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Decreased IL-12 production by DCs (Figure S3D) and decreased numbers of IL-12+ DCs (Figure S3E, F) both contributed to this reduction.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IFN-γ sensing by DCs controls IL-12 production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Intravital imaging further revealed a 12.1 ± 3.7 fold increase of IL-12p40-eYFP+ cells on day one post treatment, which persisted for at least five days (Figure 1C and S1C).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Successful aPD-1 treatment triggers endogenous IFN-γ and IL-12 responses within tumors
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“DC1s had higher expression of the granulocyte/macrophage colony-stimulating factor receptor Csf2rb compared to DC2s, and neither DC1s nor DC2s expressed the granulocyte colony-stimulating factor receptor Csf3r (Figure 2C).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in the experimental setups used in this study we found that CD8+ T cells and DCs are the primary producers of IFN-γ and IL-12, respectively”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We confirmed that IL-12+ cells had more cell surface CD40 than their IL-12– counterparts (Figure S6A) and that IL-12+ DCs expressed more CD40 than tumor-associated macrophages (Figure S6B).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Activation of the non-canonical NFkB pathway amplifies IL-12-producing DCs
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“treatment with either agonistic aCD40 mAbs or AZD5582 provided antitumor effects in vivo (Figure 7B).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Amplification of IL-12+ DCs improves cancer immunotherapy in an IL-12-dependent manner
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that combining aPD-1 with aCD40 mAbs controlled B16F10 tumor growth (Figure S7E and F) and resulted in increased mouse survival (Figure 7D), when compared to aPD-1 or aCD40 monotherapies.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Amplification of IL-12+ DCs improves cancer immunotherapy in an IL-12-dependent manner
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“since IL-12+ DCs express the highest levels of CD28’s co-stimulatory ligands, CD80 and CD86”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In total, 4095 cells (1154 untreated and 2941 aPD-1 treated cells) passed QC and were sequenced.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > METHOD DETAILS > Single Cell RNA Sequencing
Strength:plain· not yet calibratedn = 4,095Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“IFNG was not detectably increased in the post-treatment samples, which is expected from the timing of tissue collection and rapid on/off cycling of IFN-γ production by T cells (Slifka et al., 1999).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in cancer patients
What the sources say
- Not checked yetcites Slifka et al., 1999 source
Strength:plain· not yet calibratedn = 19Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found that monotherapies incompletely controlled tumor growth, whereas the combination treatment produced a complete, durable response in most animals treated (Figure 7C and Figure S7B and C).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Amplification of IL-12+ DCs improves cancer immunotherapy in an IL-12-dependent manner
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings indicate that aPD-1 delivery to tumors functionally impacts at least two non-overlapping cell populations, which respond differently to treatment: CD8+ T cells that activate the IFN- γ signaling pathway , and DC-like cells that turn on IL-12 production.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Successful aPD-1 treatment triggers endogenous IFN-γ and IL-12 responses within tumors
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This discrepancy may be due to tissue location, as we found that IL-12+ DCs expressed CD103 in lung tumor models (Figure S2D).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > scRNAseq shows DC-restricted IL-12 production
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IL-12 activates tumor-infiltrating lymphocyte effector functions in mice
What the sources say
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Together, we find an indirect aPD-1 effect on DCs; this effect was mediated through IFN-γ and is critical for IL-12 induction and, consequently , treatment response.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > IFN-γ sensing by DCs controls IL-12 production
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Collectively , these data indicate that aPD-1 treatment induces IL-12 production by DCs, and that both DCs and IL-12 critically regulate aPD-1 treatment potency .”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > DCs and IL-12 are relevant to aPD-1 therapy
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All biopsies were from University of California, San Francisco Medical Center-Mt. Zion, San Francisco, and Huntsman Cancer Institute, Salt Lake City , Utah, and were approved by each organization’s institutional review board.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedn = 19Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IL-12 production required DC sensing of IFN-γ , and, in turn, licensed effector T cell responses in both mice and cancer patients.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“targeted intratumoral delivery of IL-12 encoding plasmids is safe and has already demonstrated antitumor efficacy as monotherapy (Daud et al., 2008).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
- Not checked yetcites Daud et al., 2008 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“starting tumor volumes were normalized between treatment groups.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We suggest further that responses to immunotherapy can be improved through rational drug combinations that accentuate the crosstalk between lymphoid and myeloid immune compartments.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✗ Checkable: fails✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may be too vague to check against evidence.
In the paper
“besides their critical role for priming T cells in lymph nodes (Martin-Fontecha et al., 2003)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
- Not checked yetcites Martin-Fontecha et al., 2003 source
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“IL-12 may be both a marker and functional feature of immunostimulatory tumor DCs, based on our findings that i) IL-12+ DCs share many features with cross-presenting DC1 cells, including expression of Batf3, Irf8, Flt3, and Ly 75 (DEC205), and ii) IL-12 is required for immunotherapy efficacy”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Caveats still exist with this imaging approach however as distribution and effector functions of antibodies may differ between species and antibody compositions.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✗ Based: failsProbably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was approved by the local Ethical Review Board (Ethikkommission Nordwestschweiz) and University Hospital Basel, Switzerland.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these data linked the non-canonical NFkB pathway to antitumor intratumoral DCs and to aPD-1 treatment efficacy , and indicated that targeting non-canonical NFkB components can be therapeutic in cancer.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Amplification of IL-12+ DCs improves cancer immunotherapy in an IL-12-dependent manner
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Blood from mice was used to confirm lymphocyte trafficking defects.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > METHOD DETAILS > FTY 720 Treatments
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. The quote only partly states this claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“antitumor immune functions may not necessarily be cell type-dependent”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Strength:hedged· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data indicate that DC targeting can augment immunotherapy efficacy and sensitize tumors to aPD-1 treatment in an IL-12-dependent manner.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Results > Amplification of IL-12+ DCs improves cancer immunotherapy in an IL-12-dependent manner
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All patients consented in writing to the analysis of their tumor samples.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedn = 6Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“under different experimental contexts it is possible that NK cells may also produce IFN-γ and macrophages may also produce IL-12.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The findings presented here align with the notion that intratumoral DCs can exhibit key antitumor functions and promote aPD-1 immunotherapy.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Mouse tumors were allowed to grow to a maximum of 2 cm in diameter, or until tumor ulceration occurred. These were considered as endpoints for survival experiments in accordance with MGH IACUC regulations.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Treatments combining CD40 agonists with PD-1 pathway inhibitors (NCT03123783, NCT02376699), and cIAP inhibitors with aPD-L1 (NCT03270176), are currently in clinical trials.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
- Not checked yetcites NCT03123783
- Not checked yetcites NCT02376699
- Not checked yetcites NCT03270176
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We suggest that both treatment strategies may rely upon the non-canonical NFkB pathway and DCs.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We also showed that IL-12-producing DCs were enriched for non-canonical NFkB signaling pathway components, that the critical non-canonical NFkB kinase NIK was required for aPD-1 response, and that agonism of the non-canonical NFkB pathway in a therapeutic setting produced an IL-12-dependent antitumor response.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“prior evidence that cross- presenting tumor DCs have elevated IL-12 expression (Broz et al., 2014; Ruffell et al., 2014)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“the cDC1 subtype of DCs, which resembles the DC1 subtype presented here, is adept at cross- presenting antigens (Schlitzer and Ginhoux, 2014)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
- Not checked yetcites Schlitzer and Ginhoux, 2014
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“recent studies demonstrated that DCs can be found in tumors, where they recruit T cells and stimulate tumor-reactive T cell responses locally (Spranger et al., 2014; de Mingo Pulido et al., 2018)”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Real-time in vivo imaging allows one to identify not only primary targets of immunotherapeutics (drug pharmacokinetics) (Arlauckas et al., 2017) but also how the tumor microenvironment responds to treatment (drug pharmacody namics).”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
What the sources say
- Not checked yetcites Arlauckas et al., 2017 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Principally , we identified that aPD-1 directly induced IFN-γ production by activated T cells, but indirectly induced IL-12 production by a subset of intratumoral DCs.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Experiments were approved by the MGH Institutional Animal Care and Use Committee (IACUC) and were performed in accordance with MGH IACUC regulations.”
§ Successful anti-PD-1 cancer immunotherapy requires T cell-dendritic cell crosstalk involving the cytokines IFN-γ and IL-12 > STAR METHODS > EXPERIMENTAL MODEL AND SUBJECT DETAILS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
B cell depletion did not affect anti-CD40 therapy in this experimental model.
“We found that B cell depletion had no effect on aCD40 therapy , suggesting that B cells are not necessary for aCD40 treatment in this experimental model (data not shown).”
The paper relies on this without support.
The MC38 tumor model responds to anti-PD-1 treatment.
“Here, we initially used the MC38 mouse tumor model because it is sensitive to aPD-1 treatment and thus is relevant to define mechanisms dictating treatment success.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Interferon-γ (IFN-γ) is an important cytokine for initiating and maintaining a potent antitumor response not only through promoting CD8 + cytotoxic T cell activity and skewing toward a Th1 response but also through exerting antiproliferative, proapoptotic effects and inducing major histocompatibility complex class I (MHC I) upregulation in tumor cells (90,91).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [91]
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Immune checkpoint blockade has emerged as a critical treatment against various cancer types (Topalian et al., 2012).”
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 1×
“, 2017), neoantigen abundance (Rizvi et al., 2015), MHC class I expression (Marty et al.”
Highly parallel genome-wide expression profiling of individual cells using nanoliter droplets.
Macosko, E. Z., Basu, A., Satija, R., Nemesh, J., Shekhar, K., Goldman, M., Tirosh, I., Bialas, A. R., Kamitaki, N., Martersteck, E. M., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.002 · Cited by 7,110 · cited 1×
“All cells (n = 4,095) were clustered into unbiased cell type classifications using the Seurat single-cell analysis R package (Macosko et al., 2015).”
Spatial reconstruction of single-cell gene expression data
Satija, R., Farrell, J. A., Gennert, D., Schier, A. F., & Regev, A. (2015) · Nature Biotechnology · doi:10.1038/nbt.3192 · Cited by 7,055 · cited 3×
“REAGENT or RESOURCE SOURCE IDENTIFIER Software and Algorithms Seurat R Package (Satija et al., 2015) https://satijalab.org/seurat/; RRID: SCR_016341 FIJI ImageJ Version 1.51s FIJI https://fiji.sc; RRID: SCR_002285 SPRING (Weinreb et al., 2017) https://kleintools.hms.harvard.edu/tools/ spring.html FlowJo v.10.4 FlowJo,…”
InfluentialCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“, 2017), interferon-g (IFN-g) production (Schreiber et al., 2011; Ayers et al., 2017), neoantigen abundance (Rizvi et al.”
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671 · cited 1×
“, 2017), patient microbiota (Matson et al., 2018; Routy et al., 2018), and antibody composition (Arlauckas et al.”
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378 · cited 1×
“These inhibitory pathways are important because they protect the host from uncontrolled immune activation (Keir et al., 2008) but they can also be co-opted by tumors, which make them resist immune attack (Wherry, 2011).”
Self-citationWherry, E. J. (2011) · Nature Immunology · doi:10.1038/ni.2035 · Cited by 4,062 · cited 2×
“, 2008) but they can also be co-opted by tumors, which make them resist immune attack (Wherry, 2011).”
Molecular and genetic properties of tumors associated with local immune cytolytic activity
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G., & Hacohen, N. (2015) · Cell · doi:10.1016/j.cell.2014.12.033 · Cited by 3,825 · cited 2×
“Comparison of pre- and post-treatment samples revealed that IL-12 delivery enhanced expression of core cytolytic genes (Rooney et al., 2015) within tumors (Figures 5A and 5B).”
Flagged first, then by citations
1 of the 62 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 901–970 of 970
Spatial immune hubs defined by conserved activated dendritic cells are remodeled by immunotherapyPreprint
Minowa, T., Keshari, S., He, S., Saha, A., Shavkunov, A. S., Pineda, J. E., Yeo, Y. Y., Zhu, B., Mohanty, V., Jindal, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.10.703136
Ma, J., Xu, F., Wang, M., Zhang, S., Sang, J., Chen, H., Wen, F., Ge, R., Xie, Q., Wei, Z., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04317-y
Xue, B., Dai, L., Dai, L., & Zuo, X. (2026) · Precision Medical Sciences · doi:10.1002/prm2.70024
“63,64 In this context, TNFRSF costimulatory signals, such as 4-1BB engagement, provide complementary activation cues that potentiate cell-based therapies.”
He, J., Liu, X., Li, S., Xia, Z., Tan, X., Peng, L., Long, Q., & Wu, J. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1754912
Yang, J., Chen, S. S., Idnani, E., Shannon, S. R., Luly, K. M., Fabilane, C. S., Wilson, D. S., Spangler, J. B., Tzeng, S. Y., & Green, J. J. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201708
“28,29 No anti-tumor effect was observed for either rIL-12 dose in our study, which was unsurprising given the relatively low dosage and emphasizes the difficulty of translating rIL-12 to the clinic with its very small therapeutic window.”
Suzuki, R., Watanabe, S., Shono, K., MASUDA, T., Yanai, K., Yamazaki, R., Ando, Y., Wakabayashi, T., Tanaka, S., Sekiya, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04350-x
Xing, Q., Xie, S., Ma, J., Zhang, H., Ge, J. W., Zhao, X., Fu, Y., Xie, T., Sun, Q., Wang, X., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117095
Liu, L., Lv, W., Gong, Y., Ding, Z., Song, K., Zhao, W., Liu, H., Li, S., He, W., Yin, J., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.175447
Rôle des cellules dendritiques conventionnelles de type 1 dans l'immunosurveillance des cancers
Mattiuz, R. (2019) · theses.fr (ABES) · doi:10.70675/2685bed4zde26z40eezad12zdac1c487379e
Vermeulen, O. (2021) · theses.fr (ABES) · doi:10.70675/277aa48cz7ec5z4c99z9fe9z34e8ea73f6b5
Naour, J. L. (2022) · theses.fr (ABES) · doi:10.70675/ad2bd68az83cdz4738zb39fz6a66ef3080d3
Ruggiu, M. (2023) · theses.fr (ABES) · doi:10.70675/de84e089z4e46z475dz8d12z25950ab6f427
Kim, T.-Y., Kim, S., Lee, S., Lee, S.-H., Yu, J., Kim, K. O., & Kweon, M. (2026) · iScience · doi:10.1016/j.isci.2026.115642
Santana-Magal, N., Khateeb, A., Inbal, K., Gleiberman, A., Kaminitz, A., Weiss, T., Verbin, G., Richter, A., Zarfin, A., Farhat-Younis, L., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716539
Shin, H.-S., Kwon, S.-G., Lee, H., & Lee, J. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.06.716844
Adeleye, K. L., Oluwalana, D., Krutilina, R. I., Xie, Y., Pochampally, S., Waltz, L., Miranda‐Carboni, G. A., Miller, D. D., Seagroves, T. N., & Li, W. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119353
Zheng, X., Lan, H., Hu, Y., Qiu, T., Hou, H., & Tian, P. (2026) · Journal of Radiation Research · doi:10.1093/jrr/rrag020
Multi-armored mesenchymal stem cells potentiate antitumor immunity to combat ovarian cancer
Cao, M., Tang, Y., Li, Y., Li, J., Shen, M., Hu, L., Zhang, Y., Li, D., Wang, D., Mao, J., et al. (2026) · Stem Cell Research & Therapy · doi:10.1186/s13287-026-05028-y
“…clustering of cDC1s within the TME, where the accumulated cDC1s produce immune mediators, including CXC chemokine ligand 10 (CXCL10) and interleukin-12 (IL-12), that recruit and activate tumor-infiltrating lymphocytes (TILs) [14, 15], thereby mounting effective antitumor immune responses [16, 17].”
PRMT7 restricts CD8 + T cells expansion via the NF-κB pathwayPreprint
Srour, N., Luo, K., Allard, D., Xiong, Y., Yu, Z., Papadopoulos, T., Santinon, F., Hsieh, C.-H., Stagg, J., Barsyte-Lovejoy, D., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.04.25.720790
Jian, R., Ma, Y., Nikfarjam, M., & He, H. (2026) · Cell Communication and Signaling · doi:10.1186/s12964-026-02923-y
Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC
Zhang, Z., Ding, L., Zhong, Y., Feng, H., Huang, L., Huang, W., Wang, C., Östman, A., Wang, B., Zhou, J., et al. (2026) · Advanced Science · doi:10.1002/advs.75695
“…questions about the relative contributions of intratumoral versus lymphoid organ DC populations in mediating responses to PD-1/PD-L1 blockade [ 47–53 ], particularly given reports that LAMP3 + DCs may predict better response to immune checkpoint therapy [ 13, 54 ], though the role of PD-L1…”
Immune tolerance versus cancer surveillance: an ongoing challenge
Agrez, M. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014602
Bi, S., Tian, Y., Le, Y., Li, H., Wang, Y., Liu, C., & Zhou, H. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103658
Basic and Clinical Evidence for Perioperative Immunotherapy in Resectable HNSCC
Sakaue, S., Kono, M., Kumai, T., Inoue, T., Ominato, H., & Takahara, M. (2026) · Cancers · doi:10.3390/cancers18111845
“Multiple studies have shown that effective antitumor T-cell priming and responsiveness to ICIs depend on intact cDC1 function and crosstalk between T cells and dendritic cells within the tumor microenvironment, particularly through IFN-γ and IL-12 signaling [46–50].”
Zhang, S., Zhang, Y., Ma, M., Huang, J., Tang, R., & Hao, W. (2026) · Integrative Cancer Therapies · doi:10.1177/15347354261453338
“14 The phenotypes of these cytokine receptors on Th1, Tc1, NKT1, and NK1 following irradiation must be characterized, which presumably influence their reconstitution from irradiation, particularly in the lung TME.”
Jiang, L.-Y., Zhu, B.-Y., Zhou, L., Deng, D., Zhang, X.-Y., Chen, J., Jiang, P.-W., Wang, G.-R., Yang, Q.-M., Zhang, M.-H., et al. (2026) · Acta Pharmacologica Sinica · doi:10.1038/s41401-026-01847-0
Kumagai, K., Hamada, Y., Horie, A., Hoshi, K., & Kakimi, K. (2026) · Journal of Oral and Maxillofacial Surgery Medicine and Pathology · doi:10.1016/j.ajoms.2026.06.004
Anobile, D. P., Barbar, L., Maucotel, E., Cornec, A., Manriquez, V., Richer, W., Denizeau, J., Sedlik, C., Bories, C., Couderc, É., et al. (2026) · PLoS Biology · doi:10.1371/journal.pbio.3003860
“Hot tumors respond preferentially to ICI, as documented in NSCLC, where enrichment of PD-L1 + macrophages and dendritic cells is associated with greater sensitivity to anti-PD1 therapy [4,16–18].”
Yang, Y., Peng, J., Wei, J., Qin, J., Yang, J., Liu, M., & Wang, G. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-04722-6
“These include checkpoint blockade combinations [17], cytokine/chemokine-armored CAR-T designs and chemokine receptor engineering [25, 26], innate activation strategies and immunocytokines [23, 24], oncolytic platforms [27], and engineered nanomedicines [28, 29].”
Yamazaki, T., Minami, A., Hirota, M., Hirano, M., Sato, R., Honma, A., Ueki, H., & Shirakawa, T. (2026) · Advanced Science · doi:10.1002/advs.202524323
Zhao, R., Liu, S., Zhang, Q., Wang, W., Yang, L., Shao, X., Jia, S., & Jin, Z. (2026) · Cancer Science · doi:10.1111/cas.70462
Han, Y., Wu, P., Song, H. M., Yu, R., Liu, R., Du, Z., Liu, Z., & Gu, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1798938
The Quest to Cure Metastatic Non-Small Cell Lung Cancer With Immunotherapy
Boiarsky, D., & Vokes, N. I. (2026) · The Cancer Journal · doi:10.1097/ppo.0000000000000838
Bourque, J., Kousnetsov, R., & Hawiger, D. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741848
Metabolic–epigenetic crosstalk in innate immune cell plasticity within the tumor microenvironment
Noh, J., Lee, J., You, C., & Kang, K. (2026) · Experimental & Molecular Medicine · doi:10.1038/s12276-026-01802-3 · Cited by 1
“IFN-driven chromatin programs in the TME track with immune checkpoint blockade sensitivity or resistance, and successful anti-PD-1 therapy requires cDC1-derived IL-12 and T cell-derived IFN-γ cross-talk 170,171 .”
Zhou, X., Omer, A. M., Ouyang, X., & Wang, N. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.180567
Chemokine Landscapes of the Tumor MicroenvironmentPreprint
Altenburger, L. M., Patil, A., Jobst, J., Kfuri‐Rubens, R., Chrisikos, T. T., Taguchi, K., Ellis, M. F., Roehrle, N., Tekgüç, M., Li, Z., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.08.743563
25 Years of Cancer Immunoediting: Dendritic Cells and Macrophages Filled the Missing Gap
Kumar, V., & Stewart, J. H. (2026) · Cancers · doi:10.3390/cancers18162672
“Moreover, T cell-based immunotherapies and ICIs fail in patients with cancer having lower/defective DCs (unable to produce IL-12) in their TME/TIME (Figure 5B) [264,265].”
Emerging Trends and Novel Approaches
Kalyani, G., Kesharwani, D., Bhairam, M., & Mishra, S. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898817084126010015
Cai, Z., Wang, H., Xie, X., Wang, Y., Zhang, T., Wu, R., Xu, S., Xu, Y., Song, Y., Chen, Z., et al. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.181096
A p53R273H-selective bispecific T cell engager: Computational design and functional validation
Huynh, N., Nguyen, T.-M. T., Bui, N. T., Nguyen, T.-N. H., Tran, D. T., Nguyen, H.-N., & Nguyen, C. T. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201333
“24 By directly linking T cells to tumor cells through TSA recognition, TCEs amplify T cell-mediated tumor lysis, positioning them as a compelling tool in anticancer immunotherapy.”
Wang, X., Yang, L., Hou, Y., Wang, G., Ding, Y., Zhang, Y., Wang, S., & Hong, Z. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177716
“This process remodels the immunosuppressive tumor microenvironment and elicits a Th1-type immune response [1], thereby exerting potent antitumor effects [2] and positioning IL-12 as a highly promising candidate for cancer immunotherapy [2,3].”
Beyond cold to hot: oncolytic virotherapy as the next cornerstone of immuno-oncology
Jia, W. W.-G., Zhao, R., Kaufman, H. L., & Martuza, R. L. (2026) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-026-01198-z
“…T H1 polarization, stimulating IFNγ production by T cells and natural killer (NK) cells and, crucially, participating in an autocrine positive feedback loop: IFNγ produced by T cells and NK cells signals back to DCs to reinforce IL-12 secretion, sustaining the immunostimulatory state 91 (Fig.”
Zhao, X., Wang, H., Liu, Y., & Cao, L. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1919294
Systematic evaluation of MAIT and iNKT abundance as checkpoint blockade biomarkers
Li, Y., Chen, L., Shan, S., Wang, H., Xing, X., & Zhang, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1917317
Dendritic cells as programmable platforms for cancer immunotherapy
Liu, Y., Marcandalli, E., Liu, Y., Bayerl, F., Pittet, M. J., & Palma, M. D. (2026) · Trends in Immunology · doi:10.1016/j.it.2026.08.013
Self-citationWang, X., Liu, J., Hairulajiang, A., Wang, J., Wang, Q., Li, Z., Zou, B., & Feng, Y. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02786-4
“Responsiveness is favored when PD-1-positive cells retain TCF1 expression, proliferative competence, and access to antigen-presenting-cell niches, whereas dominance of TCF1-low terminal states is associated with limited reinvigoration [31, 69, 75].”
Integrating biology and mathematics to understand checkpoint immunotherapy
Sousa, R. S., Moshensky, A., Murat, C., Geels, S. N., Lowengrub, J. S., & Marangoni, F. (2026) · Trends in cancer · doi:10.1016/j.trecan.2026.09.004
Goldman, C. K. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2736333
Feng, C., Wang, J., Zhang, Y., & Feng, Y. (2026) · Journal of Nanobiotechnology · doi:10.1186/s12951-026-05116-4
Radiation-induced cell-death states in cancer: Toward biomarker-guided radioimmunotherapy
Wang, X., (2085), W. G., Wang, Q., He, S., & Zou, B. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218860
Liao, Y., Yang, X., & Du, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1998296
Wang, B., Zhao, D., Ma, Y., & Sui, C. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1954319
Microbiome-directed therapies in oncology: from animal models to clinical implementation
Skonieczna‐Żydecka, K., Marlicz, M., Kaczmarczyk, M., Łoniewski, I., Boluk, P., Ekstedt, N., Kutrzuba, K., & Marlicz, W. M. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102148
Klich, J. H., Nejatfard, A., Meany, E. L., Ou, B. S., Krawczyk, Z. D., Baillet, J., & Appel, E. A. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103109
“Given well-documented resistance to aPD1 monotherapy, 31,32 we pursued treatment regimen in combination with ICB to determine whether our engineering approach could improve upon standard of care.”
Nakka, P., Hobbs, B. D., Sidore, C., Palmer, W. H., Murdock, D., Gurski, L., Zaretsky, A. G., Moll, K., Campos, A. I., Joshi, A., et al. (2026) · Hepatology · doi:10.1097/hep.0000000000001819
Pherez-Farah, A., de Koning, W., Qi, W., Boncompagni, G., Dotta, E., Peroni, E., Baccega, T., Macioła, A. K., Rocca, G., Attianese, G. M. P. G., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.10.14.759124
Koskela, S. A., Kallionpää, R., Mäkelä, I., Birkman, E. ‐., Sundvall, M., & Figueiredo, C. R. (2026) · Scandinavian Journal of Immunology · doi:10.1111/sji.70153
Programmable mRNA vaccine materials for temporal control of antitumour immunity
Jeong, S. D., Tang, C., Wang, X., Szeglowski, A., Kim, Y., Kim, B., Sharma, P., Moon, J. J., Jiang, W., & Kim, B. Y. S. (2026) · Nature Reviews Materials · doi:10.1038/s41578-026-00974-8
Irianto, T., Flohr, A.-S., Reichardt, C. M., Ghuias, A., Deloch, L., Freitag, D., Amon, L., Lehmann, C. H. K., Dudziak, D., Hildner, K. M., et al. (2026) · OncoImmunology · doi:10.1080/2162402x.2026.2743436
“59,65 Ionizing radiation and adjuvant-mediated stimulation are known to induce type I interferon signaling and promote inflammatory activation of antigen-presenting cells.”
Dihydroartemisinin as a pharmacokinetically constrained immune-conditioning pulse in cancer therapy
Wei, P., Wang, J., Cao, Y., Song, Y., & Wang, Z. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1955672
Metadata
- Authors
- Garris, C. S., Arlauckas, S. P., Kohler, R. H., Trefny, M. P., Garren, S., Piot, C., Engblom, C., Pfirschke, C., Siwicki, M., Gungabeesoon, J., Freeman, G. J., Warren, S. E., Ong, S., Browning, E., Twitty, C. G., Pierce, R. H., Le, M. H., Algazi, A. P., Daud, A. I., Pai, S. I., Zippelius, A., Weissleder, R., & Pittet, M. J.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- University Hospital of Basel (CH)
- Nanostring Technologies (United States) (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2018-12
- Volume
- 49
- Issue
- 6
- Pages
- 1148-1161.e7
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC6301092
- OpenAlex
- W2904099327
- Semantic Scholar
- 1209b0cd82a4fa3c176fbcbc8f01817d21cdace6
- Cited by
- 966
- References
- 62
- Citations by year
- 2026: 101 · 2025: 118 · 2024: 130 · 2023: 138 · 2022: 146 · 2021: 150 · 2020: 124 · 2019: 57 · 2018: 1
- FWCI
- 30.99
- Type
- journal article
- Language
- en
- Update notices
- erratum (2022-09-13)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Immunity (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (acceptedVersion, other-oa)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Samana Cay MGH Research Scholar Fund
- Robert Wenner Award from the Swiss Cancer League
- NIH (R01-AI084880, R01-CA218579, R01-AI123349, R01-CA206890, R33-CA202064, U01CA206997, P01 AI056299, P50CA101942, F31-CA196035, T32-CA79443)
- Swiss National Cancer Foundation (320030_162575)
- MGH ECOR Tosteson Postdoctoral Fellowship
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- anti-PD-1 therapy, immune checkpoint blockade, tumor-infiltrating dendritic cells, IL-12, interferon-gamma, T cell-mediated antitumor immunity, NF-κB signaling, intravital imaging, single-cell RNA sequencing, pharmacodynamics, cancer immunotherapy
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Antibodies, Monoclonal, Dendritic Cells, Female, Humans, Immunotherapy, Interferon-gamma, Male, Mice, Inbred C57BL, Mice, Transgenic, Middle Aged, Neoplasms, T-Lymphocytes, Signal Transduction, NF-kappa B, Interleukin-12, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-07, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-07 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
